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Abstract
Background: The Interleukin 28B (IL28B) rs12979860 polymorphisms was recently reported to be associated with
the human T-cell leukemia virus type 1 (HTLV-1) proviral load (PvL) and the development of the HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP).
Methods: In an attempt to examine this hypothesis, we assessed the association of the rs12979860 genotypes with
HTLV-1 PvL levels and clinical status in 112 unrelated Brazilian subjects (81 HTLV-1 asymptomatic carriers, 24
individuals with HAM/TSP and 7 with Adult T cell Leukemia/Lymphoma (ATLL)).
Results: All 112 samples were successfully genotyped and their PvLs compared. Neither the homozygote TT nor
the heterozygote CT mutations nor the combination genotypes (TT/CT) were associated with a greater PvL. We also
observed no significant difference in allele distribution between asymptomatic carriers and patients with HTLV-1
associated HAM/TSP.
Conclusions: Our study failed to support the previously reported positive association between the IL28B
rs12979860 polymorphisms and an increased risk of developing HAM/TSP in the Brazilian population.
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Background
Human T-lymphotropic virus type I (HTLV-I) is an
oncogenic human retrovirus that was first isolated from
a T-cell line, HUT102, that had been obtained from a
patient with adult T-cell leukemia/lymphoma (ATLL)
[1]. Globally, there are an estimated 10–20 million indi-
viduals that carry the HTLV-I [2]. The disease burden is
unevenly distributed, with a higher incidence of the
disease particularly in southwest Japan, the Caribbean
islands, South America, and portions of Central Africa
[3]. Infection with HTLV-I may result in a spectrum of
clinical manifestations, ranging from asymptomatic in-
fection to a number of human disorders, most notably a
malignant ATLL and a chronic progressive neuromyelo-
pathy, termed HTLV-I-associated myelopathy/tropical
spastic paraparesis (HAM/TSP) [4]. The majority of
HTLV-I-infected individuals remain asymptomatic for
life, while some individuals progress to a preleukemic
phase that is characterized by small numbers of circulat-
ing leukemic cells in the peripheral blood, skin lesions,
and a lack of involvement of other organ systems [5].
Only 2.5% to 5% of the virus carriers eventually develop
ATLL after a long asymptomatic period [6,7]. The rea-
son why some people develop disease, whereas others
remain healthy, is likely dependent on both host-related
and virus-related factors [8]. Available evidence from
molecular studies indicate that the impairment of vari-
ous cellular functions by viral genes (e.g., tax and HBZ),
genetic and epigenetic changes including DNA methyla-
tion, and the host immune system may contribute to the
leukemogenesis of ATLL [9-11].
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Cytokines play an indispensable role in the defense
against viral infection, both indirectly through determin-
ation of the predominant pattern of the host response and
directly through significant inhibition of viral replication
[12]. In attempts at explaining the heterogeneity of HTLV-I
courses and outcomes, considerable attention in recent
years has been paid to the single nucleotide polymorphisms
(SNPs) in host genes that encode cytokine receptors and
human leukocyte antigen (HLA) class I and II [13-19]. For
example, multiple studies have suggested an association
between polymorphisms at the IL-6 and IL-10 promoters,
at position −634 and −592, respectively, and the pathogen-
esis of HAM/TSP [18,19]. In contrast, genetic variation
at site −592 resulted in no association in other study
analyzing the impact of these polymorphisms on the risk
of HAM/TSP in Brazilian patients [20]. In another
study, a 857 T polymorphism in tumor necrosis factor α
(TNF-α), which is a potent immuno-modulator and pro-
inflammatory cytokine, has been shown to be associated
with ATLL patients compared to healthy subjects, sug-
gesting that the genetic alteration that increases the pro-
duction of TNF-α is associated with a susceptibility to
ATLL [13].
Recently, three independent genome-wide asso-
ciation studies identified several polymorphisms, such
as rs8099917, rs12979860, and 12980275, in or near the
IL28B gene in patients infected with hepatitis C virus
genotype 1 who had previously been treated with a com
bination of pegylated IFN-α and ribavirin [21-23]. The
polymorphism rs12979860 (3 kb upstream of IL28B),
identified by Ge et al., [21] was described as the SNP
with the strongest association to sustained virological
response, which is defined as the undetectability of
HCV RNA 6 months after stopping therapy. This break-
through association has now been found in various studies
worldwide [24-27]. Interestingly, HTLV-1 infected indivi-
duals with the CT/TT allelic variants at the IL28B
rs12979860 gene exhibited approximately a 3-fold in-
creased risk of HAM/TSP and had nearly 10-fold higher
median HTLV-1 proviral loads (PvLs) than CC carriers
[28]. To investigate the consistency of this association,
we chose to further scrutinize the role of the IL28B
rs12979860 polymorphism in both asymptomatic HTLV-
1 carriers and in infected individuals that display clinical
symptoms (n =112), in correlation to PvL.
Methods
All patients were Brazilian and were recruited from the
HTLV-1 outpatient clinic at the University of Sao Paulo,
Brazil. We were unable to recruit more subjects, which
would have enhanced the power of the study, and the
total number of subjects was thus limited to 112. Thus,
our study has an 80% power to detect a minimum odds
ratio of 1.5 for the SNP, assuming α = 0.05 and the two
tailed test.
Peripheral blood samples (5 ml) were collected from
the 112 HTLV-1 positive individuals. Infected indivi-
duals were identified by the HTLV enzyme immunoas-
says Murex HTLV I + II (Abbott/Murex, Wiesbaden,
Germany) and Vironostika HTLVI/II (bioMérieux bv,
Boxtel, Netherlands), and infection was confirmed by
HTLV BLOT 2.4 (HTLV blot 2.4, Genelabs Diagnostics,
Science Park,. Singapore). Of these, 81 (72.3%) were
asymptomatic carriers (ACs), 24 (21.4%) had HAM/TSP
and 7 (6.3%) had ATLL. All ACs were diagnosed as
HTLV-1 carriers at the time of blood donation. The clin-
ical status of HAM/TSP was determined based on WHO
criteria for HTLV-1 associated diseases [29]. Diagnostic
criteria for ATLL included serologic evidence of HTLV-1
infection and cytologically or histologically proven T cell
malignancy. Written informed consent was obtained from
each participant. The study was approved by the local
review board (Comissão de Ética para Análise de Projetos
de Pesquisa, CAPPesq).
Laboratory measurements included peripheral blood
lymphocyte counts, quantitative measurement of HTLV-1
PvLs with the use of sensitive SYBR Green Real-Time
PCR with a detection limit of 1 copy per 103 PBMC cells,
and HTLV-1 genotypes [30]. The results were obtained
from the patients' medical records.
Based on the published human chromosome 19q13
sequence (NCBI Reference Sequence: NT_011109.16), a
293 base pair segment upstream of the IL-28 gene, flank-
ing the rs12979860 polymorphism between nucleotides
12006835 and 120071103, relative to the chromosome 19
translational start codon, was analyzed. This region was
PCR-amplified from genomic DNA using the forward pri-
mer 5'-GCTCAGCGCCTCTTCCTCCTGCG-3' and the
reverse primer 5'-GGCAGGGCTCCCTTCTGTGATT
GACC-3'. The PCR conditions consisted of an initial
denaturation step at 95°C for 3 minutes, followed by
35 cycles of 95°C for 30 seconds, 58°C for 30 seconds and
68°C for 1 minute, and a final extension at 68°C for 5 min-
utes. Negative controls without the DNA template were
included in each experiment. After termination of the
PCR cycle, the products were purified using a QIA quick
PCR purification kit (Qiagen). Complementary DNA
strands from each amplicon were directly sequenced by
cycle sequencing using the same primers used for the
PCR, BigDye terminator chemistry and Taq polymerase
on an automated sequencer (ABI 3130, Applied Biosys-
tems Inc., Foster City, CA), according to the protocols
recommended by the manufacturer.
Continuous variables, including PvLs, were presented as
the median (range) or mean ± standard deviation, while al-
lelic frequencies were estimated by direct allele counting
and were expressed as frequencies (%). Deviation from
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Hardy-Weinberg equilibrium was tested by a standard χ2
test with 1 degree of freedom. Differences between PvL
variables were assessed by means of Student’s t test with
the non-parametric U-Mann–Whitney test, while those
between allelic frequencies variables were evaluated
using the Pearson χ2 test with Yate's correction or Fish-
er’s exact test, when appropriate. A p value < 0.05 was
considered significant. The data were analyzed with
Stata statistical software (StataCorp, release 5.0, 1997;
Stata, College Station, TX).
Results
In total, 112 blood samples from HTLV-1 infected indi-
viduals were included in the study. The participants' ages
ranged between 24 and 73 years, and the median age
was 55 years. Females constituted 62.5% (n = 70) of the
study population. The median measurements of CD4,
CD8 and CD25 lymphocyte percentage by flow cytome-
try (FACScan, Becton-Dickinson, Cowley, Oxford) were
45%, 26%, and 22%, respectively, in 65% of subjects. The
main characteristics of the study population are given in
Table 1.
The median PvL and the frequency of clinical status
among subjects are shown in Figure 1A. The PvL levels
were significantly higher in both HAM/TSP patients
(median 60 copies/1000 PBMCs) and ATLL patients
(median 272 copies/1000 PBMCs) (p < 0.0001, for each),
compared to ACs.
In the entire group, the frequencies of the CC, CT and
TT genotypes of rs12979860 were 45%, 48% and 7%,
respectively, reflecting a C allele frequency of 93%. The
calculated distribution of the rs12979860 alleles accord-
ing to the Hardy-Weinberg equilibrium was 69% for the
C allele and 31% for the T allele. Because of the small
number of subjects who were homozygous for the TT
allele (n = 7), and because PvL values in individuals with
this genotype and in individuals that have the heterozy-
gote CT genotype were not significantly different (p = 0.4),
subjects that were homo- or heterozygotes for the T
mutated allele (CT/TT) were grouped together for further
analysis. Next, we analyzed the relationship between the
PvL levels and the rs12979860 alleles. As shown in
Figure 1B, the median HTLV-1 PvL levels did not differ
significantly between subjects carrying the rs12979860 CC
genotype (median 57.5 copies/1000 PBMCs) and patients
with a CT genotype (median 48 copies/1000 PBMCs) or a
TT genotype (median 53.5 copies/1000 PBMCs) (p = 0.7).
We further aimed to analyze the data for potential
correlates of clinical status and frequencies of the
rs12979860 SNP. To this end, a comparison was made
between patients with HAM/TSP and HTLV-1 ACs.
Because of the small number of subjects (n = 7; 2 CC,
5 CT and 1 TT), ATLL patients were excluded from
analysis. The frequency of the rs12979860 CC genotype
was 43.2% among the 81 AC subjects and 54.2% among
the 24 patients with HAM/TSP (p > 0.5). Similarly, the
frequency of the CT/TT genotypes was not appreciably
different between the two groups (p > 0.5; Figure 2).
The transcontinental subgroup A of HTLV-1a was the
major subtype accounting for 90.4% of the studied sub-
jects. No significant difference in the frequencies of the
rs12979860 genotypes identified was found in this study,
when HTLV-1 subtypes were compared.
Discussion
In this study, we sought to replicate specific findings of
association between the polymorphism rs12979860 in
the vicinity of the IL28 gene and the HTLV-1 PvL, which
is itself a predictive factor for development of HAM/
TSP or ATLL [14,32-36]. However, our data reveal no
support for association between this SNP and HTLV-1
proviral DNA levels, in Brazilian subjects, regardless of
whether they are symptomatic or are ACs. The results
also held true when the analysis was extended to compare
the rs12979860 polymorphism frequencies in patients
that have HAM/TSP, have ATLL or are asymptomatic
carriers. Recently, Treviño et al. [28] have reported a
significantly greater frequency of the CT/TT allelic vari-
ant in patients with HAM/TSP than in ACs (80% vs. 20%;
p = 0.03), and a significantly higher median HTLV-1 PvL
was found in individuals with the CT/TT variant than in
those with the CC variant (p = 0.01). In contrast to this
report, our data do not support the IL28B gene poly-
morphism as a novel genetic susceptibility marker, either
for HTLV-1-associated HAM/TSP nor ATLL, despite
involving more than twice as many cases of HAM/TSP as
the recent study [28]. The reasons for this discrepancy
remain unclear, but it is possible that the original asso-
Table 1 Characteristics of the 112 study subjects
Age. Years
Mean ± SD 51.9 ± 12.6
Median 55
Range 24-73
Gender (%)
Male 42 (37.5)
Female 70 (72.5)
Median lymphocyte subpopulations
% CD4 cells 45
% CD8 cells 26
% CD25 cells 22
Clinical status (%)
Asymptomatic carriers 81 (72.3)
HAM/TSP 24 (21.4)
ATLL 7 (6.3)
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ciations for these SNP were either due to chance or were
overestimated due to the small sample size. It seems
highly unlikely that this inconsistency in findings may
stem from different methods used to assign the
rs12979860 polymorphisms. The initial study used an al-
lelic discrimination fluorogenic probe, and we used direct
sequencing approach, which is still considered to be the
gold standard. We believe that these 2 methods are similar
to each other, and we assume that there is no difference in
the definition of the term “genotype” between the two
studies. We acknowledge that our data must be inter-
preted cautiously, and we cannot rule out sampling bias
that results from the small sample size of this study. How-
ever, we believe that if the findings of the recent study
were not due to chance, they might generalize beyond the
HTLV-1 infected subjects reported in that study. Unfortu-
nately, our study provides no support for that hypothesis
and argues that the association of the IL28B polymorph-
ism and the risk of HAM/TSP be viewed with skepticism;
many of the statistical associations between a disease and
alleles of specific genes have been irreproducible in the
past [37].
Several recent studies have also assessed the association
of the IL28B rs12979860 SNP in other viral infections in
which IFN plays a critical role, and the results of those
studies were similar to ours. For instance, the study by
Rallon et al. [38] found a nonsignificant association
between IL28B polymorphisms and neither HIV disease
progression nor HIV protection in a sample of 29 sero-
negative individuals at risk for HIV-infection and in 68
HIV-positive carriers either with or without rapid progres-
sion of immunodeficiency. Martin et al. [39] also found a
nonsignificant association between IL28B SNP and recov-
ery of hepatitis B virus (HBV) infection in a sample of 226
individuals with HBV persistence and 384 with HBV
recovery. Furthermore, Scagnolari and colleagues [31]
reported a lack of association between IL28B SNP and the
clinical course of bronchiolitis caused by respiratory syn-
cytial virus. Yet another recent study by Kamihira et al.
[40] reported that the frequency of the rs8099917, located
3 kb upstream the IL28B/IFN-l3 gene [21], had no signifi-
cant association with susceptibility to HTLV-1 infection
or the development of ATLL in the Japanese subjects.
Therefore, it is unlikely that the two SNPs (rs8099917 and
rs12979860) are predictive factor for development of
HAM/TSP or ATLL. Future studies are required to deter-
mine the extent to which differences in the ILB28
rs12980275 allelic variants frequencies between HTLV-1
infected subjects predict disease prevalence differences be-
tween populations.
Conclusions
We observed no compelling evidence of an association
between the IL28B allelic variants and HTLV-1 PvL.
Additionally, we were unable to confirm the hypothesis
that the IL28B CT/TT polymorphisms might be a gen-
etic marker for HTLV-1-associated HAM/TSP risk.
These findings do not support the clinical utility of ei-
ther testing for the IL28B in all asymptomatic HTLV-1
individuals, or closer follow-up of IL28B CT/TT carriers,
as these steps could put us at risk of diverting financial
resources from research areas that might make more of a
Figure 1 Distribution of HTLV-1 proviral load levels among study subjects. (A) Box and Whiskers plot of HTLV-1 proviral load in
asymptomatic HTLV-1 carriers, HTLV-1–associated myelopathy/tropical spastic paraparesis patients and Adult T Cell Leukemia/Lymphoma.
(B) Interleukin 28B CC versus CT/TT allelic variants.
Figure 2 Comparison of the frequencies of interleukin (IL) 28B
rs12979860 CC and CT/TT allelic variants between
asymptomatic HTLV-1 carriers and HTLV-1–associated
myelopathy/tropical spastic paraparesis patients.
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difference in our understanding of the etiological mechan-
isms of HTLV-1 associated disease.
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